Key facts
- Greenphage’s last known valuation is $5.4M (Mar 2025).
- It has raised $3.3M; the latest was Later Stage VC ($2.1M) in Mar 2025.
- Notable investors include IRDI Capital Investissement, Boost Invest MedVallée, Business & Innovation Center, CleanTech Vallée, Greentech (France).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Greenphage
- ·The full record, as it builds
Funding rounds
No funding rounds for Greenphage are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Greenphage
Developer of a precision antibacterial compound designed to deliver selective action on specific bacterial species or strains. The company offers targeted antibacterial action that preserves the bacterial ecosystem, with natural and biodegradable residues, enabling businesses to address specific antibacterial needs with precision and reliability.
- Sector
- Healthcare
- HQ
- Clapiers, France
- Founded
- 2017
- Employees
- 6
- Website
- greenphage.com/
- Ownership
- Privately Held (backing)
Greenphage doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Greenphage shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Greenphage in its N-PORT filings yet. We sweep new filings monthly.